Antibodies to OPGL

• US 7,364,736 B2
• Filed: 06/25/2002
• Issued: 04/29/2008
• Est. Priority Date: 06/26/2001
• Status: Expired due to Term

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Fremont Inc. (Amgen Inc.), Amgen Inc.
• Inventors: Boyle, William J., Martin, Francis H., Davis, C. Geoffrey, Corvalan, Jose R.
• Primary Examiner(s): Ewoldt; G. R.
• Assistant Examiner(s): SZPERKA, MICHAEL EDWARD
• Application Number:
  US10/180,648
• Publication Number:
  US 20040033535A1
• Time in Patent Office: 2,135 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: C07K 16/241 : Tumor Necrosis Factors
• CPC Class Codes: C07K 16/2875 : against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 against NGF C07K16/22, against TNF C07K16/241
• CPC Class Codes: C07K 2317/21 : from primates, e.g. man
• CPC Class Codes: C07K 2317/51 : Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/515 : Complete light chain, i.e. VL + CL
• CPC Class Codes: C07K 2317/54 : F(ab')2
• CPC Class Codes: C07K 2317/55 : Fab or Fab'
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/622 : Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

Claims

1. An isolated antibody comprising:

a) a heavy chain comprising the amino acid sequence of SEQ ID NO;

2; and

b) a light chain comprising the amino acid sequence of SEQ ID NO;

4.

19. A pharmaceutical composition comprising the antibody of any one of claims 1, 2, 3, and 11.

20. The pharmaceutical composition of claim 19, wherein the composition comprises an acetate buffer.

21. The pharmaceutical composition of claim 19, wherein the composition comprises polysorbate.

22. The pharmaceutical composition of claim 19, wherein the composition comprises sorbitol.

23. The pharmaceutical composition of claim 19, wherein the composition comprises acetate and sorbitol.

24. The pharmaceutical composition of claim 19, wherein the composition is contained in a prefilled syringe.

25. The pharmaceutical composition of claim 19, wherein the composition is in unit dose form.

2. An isolated antibody consisting of:

a) a heavy chain consisting of the amino acid sequence of SEQ ID NO;

2; and

b) a light chain consisting of the amino acid sequence of SEQ ID NO;

4.

3. An isolated antibody comprising:

a) a heavy chain comprising the amino acid sequence of SEQ ID NO;

13; and

b) a light chain comprising the amino acid sequence of SEQ ID NO;

14.

4. The antibody of claim 3, wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody.

5. The antibody of claim 4, which is a single-chain Fv antibody.

6. The antibody of claim 3, which is a Fab antibody.

7. The antibody of claim 3, which is a Fab′

antibody.

8. The antibody of claim 3, which is a F(ab′

)₂ antibody.

9. The antibody of claim 3, which is fully human.

10. The antibody of claim 3, wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR).

11. An isolated antibody comprising:

a) a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO;

13; and

b) a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO;

14.

12. The antibody of claim 11, wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody.

13. The antibody of claim 12, which is a single-chain Fv antibody.

14. The antibody of claim 11, which is a Fab antibody.

15. The antibody of claim 11, which is a Fab′

antibody.

16. The antibody of claim 11, which is a F(ab′

)₂ antibody.

17. The antibody of claim 11, which is fully human.

18. The antibody of claim 11, wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR).